This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Drug maker Celltrion seeks revocation of Novartis’ asthma treatment patent in UK trial

By Abhishek Kumar ( October 25, 2024, 15:30 GMT | Insight) -- Celltrion, a South Korean pharmaceutical company, asked the UK High Court to invalidate an asthma treatment patent jointly owned by drugmakers Greentech and Novartis. In opening arguments today, Celltrion claimed it did not infringe and that the patent is invalid. Greentech and Novartis countered that Celltrion seeks revocation to clear the way for launching its own, competing biosimilar product.South Korean drugmaker Celltrion today asked the UK High Court to revoke a patent associated with the injectable prescription asthma drug XOLAIR on grounds of obviousness over prior art, insufficiency, and containing added matter....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections